Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% compared to the benchmark index [4][7]. Core Insights - The company reported a significant increase in Q1 2025 performance, with revenue reaching 366 million yuan, a year-on-year growth of 62.51%, and a net profit attributable to shareholders of 169 million yuan, up 66.25% year-on-year [1]. - The company launched a new freeze-dried fiber product aimed at addressing eye area aging, and has received approval for multiple types of gel products, positioning itself as a leader in the industry [2]. - A stock option incentive plan was introduced, targeting 87 employees, which represents 10.57% of the total workforce, to align core talent with the company's long-term goals [3]. Financial Performance Summary - For Q1 2025, the gross margin was 90.11%, with a net profit margin of 45.89%. The company effectively managed its expenses, with a sales expense ratio of 21.33% and a management expense ratio of 8.26% [1]. - The financial forecast estimates revenues of 2.13 billion yuan in 2025, with a projected net profit of 1.07 billion yuan, reflecting a year-on-year growth of 46.40% [6]. - The expected earnings per share (EPS) for 2025 is 12.11 yuan, with corresponding price-to-earnings (P/E) ratios of 33, 25, and 20 for the years 2025, 2026, and 2027 respectively [4][6].
锦波生物：2025年一季报点评：一季度业绩高增，激励计划彰显长期信心-20250424